89 related articles for article (PubMed ID: 23429375)
21. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
22. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes.
Wang H; Wang X; Xu X; Lin G
Ann Hematol; 2010 Jul; 89(7):671-9. PubMed ID: 20179929
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
[TBL] [Abstract][Full Text] [Related]
24. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
[TBL] [Abstract][Full Text] [Related]
25. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
[TBL] [Abstract][Full Text] [Related]
27. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
28. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
29. Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome.
Cakar MK; Yegin ZA; Baysal NA; Altındal S; Pamukçuoğlu M; Celik B; Yenicesu I
Transfus Apher Sci; 2013 Jun; 48(3):397-401. PubMed ID: 23619324
[TBL] [Abstract][Full Text] [Related]
30. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
32. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
33. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
34. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
36. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
37. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
38. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients.
Belli CB; Bengió R; Aranguren PN; Sakamoto F; Flores MG; Watman N; Nucifora E; Prates MV; Arbelbide J; Larripa I
Am J Hematol; 2011 Jul; 86(7):540-5. PubMed ID: 21674572
[TBL] [Abstract][Full Text] [Related]
39. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
40. [Expression of stromal cell derived factor-1/CXCR4 biology axis in myelodysplastic syndromes].
Zhang YZ; Da WM; Zhao DD; Zhao HF; Wu XX; Wang H
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(46):3275-7. PubMed ID: 22333149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
